Performance of 18 F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer

Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):16-17. doi: 10.1007/s00259-019-04540-z. Epub 2019 Oct 17.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cyclobutanes*
  • Humans
  • Male
  • Positron-Emission Tomography
  • Prostatic Neoplasms*
  • Prostatic Neoplasms, Castration-Resistant*

Substances

  • Cyclobutanes

Associated data

  • ClinicalTrials.gov/NCT02578940